Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis, Kite Neck-And-Neck In CAR-T Race; Deaths Keep Juno In Third Place

Executive Summary

Novartis and Kite both are set to submit their CD19-targeting CAR-T therapies for US FDA approval in early 2017, while neurotoxic deaths for two of Juno’s product candidates cast doubts on its programs.

Advertisement

Related Content

Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval
BLA Accepted: Novartis Inches Ahead In CAR-T Race With Kite
Kite Flies CAR-T Into Asia With Daiichi Sankyo, Fosun Deals
Cellectis Files IND For Talen-Edited 'Off-The-Shelf' CAR-T Candidate
Scrip's Pharma Influencers Of 2016
ASH 2016 Preview: Don't Miss These 10 Data Presentations
Juno Stresses Differences Between Its CAR-Ts As JCAR015 Trial Put On Hold Again
New Interim CAR-T Data Support Kite’s BLA Submission Plans
INTERVIEW: Juno CEO Hans Bishop On The CAR-T Learning Curve
Three Deaths In Trial Mean Clinical Hold For Juno’s Lead CAR-T Therapy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097791

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel